Capricorn Fund Managers Ltd Makes New Investment in Nuvation Bio Inc. $NUVB

Capricorn Fund Managers Ltd bought a new position in shares of Nuvation Bio Inc. (NYSE:NUVB) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 1,588,854 shares of the company’s stock, valued at approximately $14,236,000. Nuvation Bio accounts for approximately 3.4% of Capricorn Fund Managers Ltd’s holdings, making the stock its 4th biggest holding. Capricorn Fund Managers Ltd owned about 0.46% of Nuvation Bio at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Parallel Advisors LLC boosted its stake in Nuvation Bio by 51.9% during the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock worth $28,000 after acquiring an additional 2,597 shares during the last quarter. Swiss Life Asset Management Ltd acquired a new stake in Nuvation Bio in the third quarter worth $39,000. Northwest Quadrant Wealth Management LLC acquired a new stake in Nuvation Bio in the third quarter worth $40,000. HBK Sorce Advisory LLC bought a new position in shares of Nuvation Bio during the third quarter worth $42,000. Finally, Federated Hermes Inc. grew its holdings in shares of Nuvation Bio by 75.9% in the 3rd quarter. Federated Hermes Inc. now owns 11,630 shares of the company’s stock valued at $43,000 after buying an additional 5,020 shares during the period. 61.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Royal Bank Of Canada upped their price objective on shares of Nuvation Bio from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Tuesday, March 3rd. UBS Group decreased their target price on Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating for the company in a research note on Tuesday, March 3rd. Truist Financial set a $13.00 price target on Nuvation Bio in a report on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvation Bio in a research report on Thursday, January 22nd. Finally, HC Wainwright cut their price objective on Nuvation Bio from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, January 12th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $11.63.

Nuvation Bio Trading Up 0.8%

Shares of NYSE:NUVB opened at $4.45 on Monday. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -7.41 and a beta of 1.60. Nuvation Bio Inc. has a 12 month low of $1.54 and a 12 month high of $9.75. The company’s fifty day simple moving average is $5.06 and its 200 day simple moving average is $5.75. The company has a quick ratio of 6.81, a current ratio of 6.95 and a debt-to-equity ratio of 0.15.

Nuvation Bio (NYSE:NUVB) last announced its earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). Nuvation Bio had a negative net margin of 325.31% and a negative return on equity of 57.48%. The firm had revenue of $41.87 million during the quarter, compared to analyst estimates of $36.82 million. As a group, research analysts forecast that Nuvation Bio Inc. will post -0.36 EPS for the current fiscal year.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.